Payment overview · 2025
General Payments
$3,163.41
139 reported records · 45 companies
Healthcare provider profile · identity verified
Adarsh Jha, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · EAST HARTFORD, CT · NPI 1710188685
Verified facts
What the public records show
CMS Open Payments records show Adarsh Jha, M.D. received $3,163.41 in general payments during 2025 across 139 reported records.
Abbott Laboratories accounted for 10.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 64 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus, Synthroid, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Prolia by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Unithroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $343.68 | 10.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $284.24 | 9.0% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $273.95 | 8.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $210.10 | 6.6% | 8 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $156.52 | 5.0% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $147.85 | 4.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $144.86 | 4.6% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $116.78 | 3.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $98.27 | 3.1% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $86.74 | 2.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.76 | 2.3% | 3 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.75 | 2.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.54 | 2.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.39 | 2.0% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $63.34 | 2.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.48 | 1.9% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $58.74 | 1.9% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $57.30 | 1.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.32 | 1.7% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $52.32 | 1.6% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $48.01 | 1.5% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $44.75 | 1.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $43.83 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.79 | 1.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.26 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $33.38 | 1.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.57 | 1.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $29.68 | 0.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.19 | 0.9% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $29.06 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.23 | 0.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $25.16 | 0.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $24.60 | 0.8% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $24.37 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.31 | 0.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.58 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.58 | 0.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.35 | 0.7% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $20.75 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.6% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $19.20 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.32 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.15 | 0.6% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.48 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,028.46 | 136 |
| Education | $85.00 | 2 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $293.73 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $214.21 | 16 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $167.32 | 8 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $156.52 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $146.21 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $140.91 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $129.28 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $119.64 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $117.75 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.75 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $116.78 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $88.39 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $86.74 | 4 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC, Alvogen Inc | $76.50 | 4 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $71.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $64.39 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $63.34 | 3 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $58.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.32 | 3 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $48.01 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $48.01 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $48.01 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $43.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $34.26 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.19 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.57 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $29.68 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.97 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 363 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 58 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 253 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
253 | 62 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
152 | 95 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
363 | 75 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 363 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 103 |
| Metformin Hcl Er | Metformin Hcl | 281 | 89 |
| Synthroid | Levothyroxine Sodium | 253 | 62 |
| Jardiance | Empagliflozin | 223 | 55 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 173 | 70 |
| Alendronate Sodium | Alendronate Sodium | 155 | 53 |
| Prolia | Denosumab | 152 | 95 |
| Tresiba Flextouch U-200 | Insulin Degludec | 148 | 41 |
| Metformin Hcl | Metformin Hcl | 144 | 36 |
| Humalog Kwikpen U-100 | Insulin Lispro | 130 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 36 |
| Novolog Flexpen | Insulin Aspart | 104 | 41 |
| Tresiba Flextouch U-100 | Insulin Degludec | 102 | 28 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 85 | 33 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 29 |
| Unithroid | Levothyroxine Sodium | 81 | 21 |
| Trulicity | Dulaglutide | 77 | 18 |
| Farxiga | Dapagliflozin Propanediol | 76 | 22 |
| Prednisone | Prednisone | 72 | 17 |
| Januvia | Sitagliptin Phosphate | 69 | 23 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 68 | 21 |
| Rybelsus | Semaglutide | 58 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 56 | 17 |
| Testosterone | Testosterone | 56 | 20 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 46 | 15 |
| Glipizide Er | Glipizide | 44 | 13 |
| Lisinopril | Lisinopril | 44 | 13 |
| Risedronate Sodium | Risedronate Sodium | 37 | 14 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | 11 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 33 | suppressed |
| Methimazole | Methimazole | 32 | 16 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Cabergoline | Cabergoline | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | 12 |
| Somatuline Depot | Lanreotide Acetate | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Cytomel | Liothyronine Sodium | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 11 |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,163.41 · 139 records | Abbott Laboratories | ACCRUFER, ACTHAR, AFREZZA, AREXVY, Auvelity, CAPLYTA, CRENESSITY, CRYSVITA, CeQur Simplicity, Cologuard Collection Kit, EVENITY, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GENOTROPIN, GLASSIA, GLYCATE, GVOKE HYPOPEN, IMCIVREE, INGREZZA, ISTURISA, JARDIANCE, MINIMED 780G, MOUNJARO, MYCAPSSA, NUCALA, OFEV, OPSUMIT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PROLIA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, SOMAVERT, STRENSIQ, SYNTHROID, TEPEZZA, TERIPARATIDE, TRELEGY ELLIPTA, TWIIST, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, UNITHROID, UPTRAVI, VYKAT XR, Veozah, WAKIX, Wegovy, XIFAXAN, YUPELRI, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error